Johnson & Johnson (NYSE: JNJ) and Philip Morris International (NYSE: PM) are two such reliable dividend payers. At $435 billion (by market capitalization), healthcare titan Johnson & Johnson is a favorite of many dividend investors for several reasons. The pharmaceutical segment is led by immunology drugs such as Stelara and Tremfya, and cancer drugs such as Darzalex and Imbruvica (which is co-owned by Johnson & Johnson and AbbVie).
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting